Trial Profile

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 17 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rucaparib (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms ROAR

Most Recent Events

03 May 2024 Results demonstrated acceptable toxicity and efficacy of Rucaparib in patients with biochemically recurrent nonmetastatic prostate cancer, published in the Oncologist
23 Jun 2023 Planned End Date changed from 1 Jul 2023 to 12 Jan 2024.
18 Feb 2023 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com